Castle Biosciences Inc CSTL

US Health Care

$35.81 ▲ +1.76% (+$0.62)

Open $35.19

Prev Close $35.19

Day Range $34.44 – $36.12

52W Range $17.72 – $44.28

Market Cap $1.09B

Beta 1.05

EPS (TTM) $-0.65

📋 Company Profile

Industry	Health Care
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2019-07-25
Shares Out.	30,330,000
Website	castlebiosciences.com/ ↗
Phone	13026365400
Employees	1,002
Revenue	$103.5M
Gross Profit	$79.8M
Net Income	-$2.1M
Free Cash Flow	-$489,000
Total Assets	$561.2M
Total Liabilities	$91.1M
Equity	$470.0M

About Castle Biosciences Inc

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.

Castle Biosciences Inc is a publicly traded company under the ticker symbol CSTL on the NASDAQ NMS - GLOBAL MARKET, operating in the Health Care industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.